Karyopharm Therapeutics Inc. — Net Income by Fiscal Year
14 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/970fae17-4209-4e05-a214-71838515efc6/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-196.0M | 2025-01-01 – 2025-12-31 | evidence 0001503802-26-000023 |
| FY 2024 | $-76.4M | 2024-01-01 – 2024-12-31 | evidence 0001503802-26-000023 |
| FY 2023 | $-143.1M | 2023-01-01 – 2023-12-31 | evidence 0001503802-26-000023 |
| FY 2022 | $-165.3M | 2022-01-01 – 2022-12-31 | evidence 0000950170-23-003129 |
| FY 2021 | $-124.1M | 2021-01-01 – 2021-12-31 | evidence 0000950170-22-002548 |
| FY 2020 | $-196.3M | 2020-01-01 – 2020-12-31 | evidence 0001193125-21-054811 |
| FY 2019 | $-199.6M | 2019-01-01 – 2019-12-31 | evidence 0001193125-20-049115 |
| FY 2018 | $-178.4M | 2018-01-01 – 2018-12-31 | evidence 0001193125-19-057610 |
| FY 2017 | $-129.0M | 2017-01-01 – 2017-12-31 | evidence 0001193125-18-084024 |
| FY 2016 | $-109.6M | 2016-01-01 – 2016-12-31 | evidence 0001193125-17-084396 |
| FY 2015 | $-118.2M | 2015-01-01 – 2015-12-31 | evidence 0001193125-16-505181 |
| FY 2014 | $-75.8M | 2014-01-01 – 2014-12-31 | evidence 0001193125-15-091264 |
| FY 2013 | $-33.9M | 2013-01-01 – 2013-12-31 | evidence 0001193125-15-091264 |
| FY 2012 | $-15.9M | 2012-01-01 – 2012-12-31 | evidence 0001193125-15-091264 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
Karyopharm Therapeutics Inc. — all facts · Revenue · Operating Income